Gimv joins a $92M Series A financing round led by Novo Holdings to support the development of antibody-drug conjugate (ADC) programs in oncology utilizing a clinically validated platform designed to minimize off-target toxicity and improve efficacy. 

Kivu Bioscience (https://kivubioscience.com) is a biotech company headquartered in San Francisco that develops next-gen antibody-drug conjugates (ADCs) in oncology to deliver best-in-class therapeutics. Today, the company announces the close of a $92 million Series A financing round led by Novo Holdings and further joined by Gimv, Red Tree, HealthCap, BioGeneration Ventures, Merck Ventures, and Brabantse Ontwikkelings Maatschappij (BOM).

Michaël Vlemmix, Partner Life Sciences, declares: “I am thrilled to work alongside co-investors and the management team to build Kivu into a leading ADC company. Its ambition holds great potential to significantly enhance patient outcomes in the future.” 

Christoph Kocher, Principal Life Sciences further adds: “We are excited to be using the clinically derisked technology of Synaffix in our first two programs that are aimed to show robust clinical proof of concept with this financing.”

Bram Vanparys, Head of Life Sciences, adds: “Our new investment in Kivu Bioscience aligns perfectly with our strategic vision for Gimv’s Life Sciences Platform. This investment represents a significant step forward in our commitment to advancing therapeutic solutions for cancer patients. We are excited about the potential this investment holds for driving impactful advancements and delivering value to our stakeholders.”

For more information, please read the full press release from Kivu Bioscience attached.

https://www.gimv.com/sites/default/files/media/241028_PR_Kivu_BioScience_EN.pdf